Arcedi Biotech ApSAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Selskabsskat
indkomstår 2024Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2017–2025
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Balance — aktiver | |||||||||
| Likvide beholdninger | 87.000 | 972.000 | 1.961.000 | 945.000 | 2.486.000 | 1.537.000 | 1.649.000 | 1.270.000 | 540.000 |
| Omsætningsaktiver i alt | 3.738.000 | 6.519.000 | 7.369.000 | 6.024.000 | 7.977.000 | 9.803.000 | 12.038.000 | 12.294.000 | 9.528.000 |
| Anlægsaktiver i alt | 35.086.000 | 51.747.000 | 71.337.000 | 88.559.000 | 106.944.000 | 116.616.000 | 125.115.000 | 123.626.000 | 121.682.000 |
| Aktiver i alt | 38.824.000 | 58.266.000 | 78.706.000 | 94.583.000 | 114.921.000 | 126.419.000 | 137.153.000 | 135.920.000 | 131.210.000 |
| Balance — passiver | |||||||||
| Kortfristede gældsforpligtelser | 43.912.000 | 66.593.000 | 87.296.000 | 106.214.000 | 131.606.000 | 6.322.000 | 7.185.000 | 4.670.000 | 1.332.000 |
| Langfristede gældsforpligtelser | — | — | 306.000 | 0 | — | 164.864.000 | 211.217.000 | 259.008.000 | 303.518.000 |
| Gældsforpligtelser i alt | 43.912.000 | 66.593.000 | 87.602.000 | 106.214.000 | 131.606.000 | 171.186.000 | 218.402.000 | 263.678.000 | 304.850.000 |
| Selskabskapital | 80.000 | 80.000 | 80.000 | 80.000 | 80.000 | 80.000 | 80.000 | 80.000 | 80.000 |
| Overført resultat | -26.585.000 | -45.034.000 | -63.679.000 | -80.137.000 | -99.348.000 | -125.046.000 | -162.642.000 | -204.440.000 | -250.458.000 |
| Årets resultat | -4.677.000 | -5.787.000 | -3.762.000 | -3.853.000 | -5.779.000 | -24.201.000 | -32.471.000 | -41.961.000 | -45.882.000 |
| Egenkapital i alt | -9.943.000 | -15.729.000 | -19.493.000 | -23.346.000 | -29.125.000 | -53.326.000 | -85.797.000 | -127.758.000 | -173.640.000 |
| Resultatopgørelse | |||||||||
| Bruttofortjeneste | 595.000 | 1.914.000 | 5.230.000 | 4.903.000 | 3.864.000 | -8.906.000 | -7.228.000 | -12.655.000 | -11.636.000 |
| Resultat af primær drift | -5.292.000 | -5.766.000 | -3.548.000 | -4.549.000 | — | -29.568.000 | -31.892.000 | -37.459.000 | -38.236.000 |
| EBITDA | -5.292.000 | -5.719.000 | -3.453.000 | -4.454.000 | — | -22.779.000 | -23.664.000 | -28.667.000 | -29.045.000 |
| Resultat før skat | -5.987.000 | -6.812.000 | -4.891.000 | -6.316.000 | -8.880.000 | -33.236.000 | -42.216.000 | -50.714.000 | -50.245.000 |
| Årets resultat | -4.677.000 | -5.787.000 | -3.762.000 | -3.853.000 | -5.779.000 | -24.201.000 | -32.471.000 | -41.961.000 | -45.882.000 |
| Personaleomkostninger | 5.887.000 | 7.633.000 | 8.683.000 | 9.357.000 | 10.403.000 | 13.873.000 | 16.436.000 | 16.012.000 | 17.409.000 |
| Af- og nedskrivninger | 0 | 47.000 | 95.000 | 95.000 | 95.000 | 6.789.000 | 8.228.000 | 8.792.000 | 9.191.000 |
| Andre nøgletal | |||||||||
| Ansatte | 9 | 13 | 14 | 15 | 17 | 24 | 23 | 22 | 22 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025Business reviewARCEDI is an advanced diagnostics company and a first mover in cell-based non-invasive prenatal testing (cb-NIPT). The Company has developed and commercialized EVITA TEST COMPLETE®, the world’s first clinically validated cell-based NIPT solution, enabling true fetal genotyping from gestational week 10 through isolation and analysis of intact fetal cells from maternal blood. EVITA TEST COMPLETE® provides diagnostic-level genomic insight non-invasively and addresses a significant unmet need in prenatal care. Approximately 2.2% of pregnancies are affected by serious genetic diseases, many of which remain undetected prenatally using conventional cell-free NIPT (cf-NIPT) and current screening protocols. This represents a substantial unmet need for improved prenatal screening both in Denmark and internationally. ARCEDI’s technology enables genome-wide detection of aneuploidies, high-resolution detection of pathogenic copy number variations (pCNVs), and detection of selected monogenic diseases through an ISO 15189–accredited and scalable laboratory workflow. In 2025, ARCEDI continued commercial operations in Denmark through private clinics in the out-of-pocket market. Future growth is expected to be driven by enhanced product differentiation through improved analytical resolution and accelerated international expansion. During 2025, the Company completed development work that significantly enhanced test performance: • Genome-wide detection of pathogenic copy number va
Financial review The company’s income statement for the year ending 31 December 2025 shows a loss of TDKK 45.882 reflecting continued investments in technology development, regulatory readiness and international business development. The balance sheet on 31 December 2025 shows negative equity of TDKK 173.640.In 2026, ARCEDI’s objective is to transition from a primarily R&D-focused organization to an internationally scalable diagnostics company. Key priorities include execution of the GENIUS project in Denmark, further expansion of the monogenic panel and continued international commercial development. The company is financed by its owners, who also provide the liquidity required for the continued operations and realization of the planned activities. Management expects that equity will be reestablished by means of own earnings.
Uddrag af ledelsesberetningen i den seneste årsrapport.